Abstract. Hepatitis C virus (HCV) translation initiation depends on an internal ribosome entry site (IRES). We previously identified an RNA molecule (HH363 -10) able to bind and cleave the HCV IRES region. This paper characterizes its capacity to interfere with IRES function. Inhibition assays showed that it blocks IRES activity both in vitro and in a human hepatoma cell line. Although nucleotides involved in binding and cleavage reside in separate regions of the inhibitor HH363 -10, further analysis demonstrated the strongest effect to be an intrinsic feature of the entire molecule; the abolishment of either of the two activities resulted in a reduction in its function. Probing assays demonstrate that HH363 -10 specifically interacts with the conserved IIIf domain of the pseudoknot structure in the IRES, leading to the inhibition of the formation of translationally competent 80S particles. The combination of two inhibitory activities targeting different sequences in a chimeric molecule may be a good strategy to avoid the emergence of resistant viral variants.
Introduction
Hepatitis C virus (HCV) infection affects more than 170 million people worldwide. Current treatments show poor efficacy due to the highly active dynamics of the HCV populations that promote the appearance of drug-resistant variants [1] . This problem, also faced in control of other viral infections, has prompted an intensive search for new drugs and alternative therapeutic strategies. Combination approaches are currently considered excellent candidates to reduce the chance of viral evasion. The HCV genome is a 9500-nucleotide (nt)-long (+) single-stranded (ss) RNA molecule. During early viral infection, uncapped viral RNAs initiate their translation using a highly conserved internal ribosome entry site (IRES) located at the 5' untranslated region (UTR; Fig. 1 ; [2, 3] ), which includes from nt 40 to 372 of the viral genome [4, 5] . It has a complex secondary and tertiary structure that acts as a scaffold for recruiting multiple protein factors during the initiation of translation [6] . This mechanism considerably differs from that used by the cellular capped mRNAs, rendering it a potential candidate for antiviral therapies. The use of RNA molecules as gene inactivation agents is a therapeutic option that has been investigated in depth [7] . Antisense RNAs and siRNAs have been proved to effectively inhibit replication of several viruses, including HCV [8] . These molecules work by sequence complementarity and in many cases viruses promptly escape the treatment [9 -13] . Viral targeting with other RNA molecules like ribozymes and aptamers has also been accomplished with different success [8] . In contrast to antisense and siRNAs, aptamers do not operate only by sequence complementarity, but also by the recognition of secondary and tertiary structures. The formation of productive complexes is a major requisite for the correct functioning of aptamers and ribozymes. These features contribute to diminishing the chance of appearance of resistant viral mutants. An additional issue in minimizing the risk of the emergence of escape variants is the use of several inhibitors with different specificities [14 -16] . We previously designed a novel combined approach [17] . An in vitro selection method was employed to isolate a collection of RNA molecules composed of a hammerhead ribozyme (named HH363) targeting positions 357 -369 of the HCV genome, plus an aptamer for the 5'UTR that carries complementary nucleotides to unique sequences in the IRES domain [17] . In the present study, the selected variants have been assayed for their ability to interfere with IRES function. This has allowed the identification of a very potent inhibitor designated as HH363 -10, which behaves as an aptamer with complementary sequences to domain IIIf of the 5'UTR (Ap10 ; Fig. 1 ; [17] ). This region participates in the formation of a pseudoknot structure essential for IRES function [18] . It has been proposed that the IIIf domain interacts with the 40S ribosomal subunit [19, 20] and favors the formation of active translational 80S complexes [21] . This is the first report of an RNA molecule that combine two functional modules that interact with different regions of the HCV IRES, interfering with its function both in vitro and in a human liver cell line.
Materials and methods
DNA templates and RNA synthesis. All RNAs were synthesized by in vitro transcription and purified as previously described [22] . DNA templates for the HCV-derived RNAs 5'HCV-691 and 5'HCV-691gg were obtained as previously described [17] . The template for RNA 667 was derived from the pcDNA3 vector (Invitrogen) linearized with DraIII. The coding sequence for IRES-FLuc was obtained by PCR amplification of the plasmid pCMVCatIREcLuc [17] . The pRLSV40 vector (Promega) was linearized with BamH1 for the synthesis of RLuc mRNA. The DNA templates for the HH363 -10 and HH363 inhibitory RNAs were obtained as described in [17] ). The dsDNAs used for the synthesis of Ap10, HH363 m-10, HH363 -10 m and HH363 m-10 m were generated by annealing and extension as previously described [23] , of oligonucleotide T7GG (5'-taatacgactcactatagg-3') with T7Ap10 (5'-GTAGGA-
; the T7 promoter sequence is underlined; lower case letters indicate the complementary sequences. The plasmid pBSSK was digested with the restriction enzyme BamH1 for the synthesis of RNA 80 . The RNA molecules employed in the inhibition assays were obtained using the RiboMAX TM -T7 large-scale RNA production system (Promega); the manufactur- In vitro translation assays. IRES-FLuc and RLuc mRNAs were translated using the Flexi rabbit reticulocyte lysate system (Promega). Reactions proceeded in 6-ml volumes containing 4 ml cell extract, 0.1 ml of the provided amino acid mixture lacking methionine (1 mM), and 0.1 ml (1.5 mCi) of a mixture of L-[ ] in vitro cell labeling kit, GE Healthcare). KCl was supplemented to 100 mM. The RNA templates for the synthesis of either FLuc (IRESFLuc) or RLuc (RNA RLuc) proteins were added to give a final concentration of 30 ng/ml (~40 nM) and 20 ng/ml (~60 nM), respectively. Inhibitory RNA concentrations ranging from 10 nM to 5 mM were assayed. All the RNA molecules were subjected to a denaturing step at 658C for 10 min and subsequently incubated at 48C for 15 min prior to their incorporation into the translation mix. Translation proceeded at 308C for 60 min. Reactions were stopped by cooling on ice and the protein products resolved on 12.5 % (w/ v) denaturing polyacrylamide gels. Dried gels were scanned in a Phosphorimager (Storm 820, GE Healthcare) and quantified with Image Quant 5.2 software (GE Healthcare). The IC 50 values were calculated with SigmaPlot 8.02 software using the equation y = y max /(1 + 10 (LogIC 50 -X) ), where y max is the maximum percentage of FLuc relative synthesis, IC 50 the inhibitor concentration that produces 50 % of the maximum observed effect, and X the inhibitor concentration.
IRES cleavage assays.
Cleavage experiments proceeded in the presence of rabbit reticulocyte lysates (RRL) under in vitro translation reaction conditions. All were performed in the presence of 40 nM 32 Pinternally radiolabeled RNA substrate 5'HCV-691. Substrates and inhibitor RNAs were denatured and renatured as described above. After 60 min at 308C, reactions were stopped on ice and the RNA molecules were extracted with phenol. Cleavage products were resolved on 4 % denaturing polyacrylamide gels, which were subsequently dried and analyzed as above.
RNA-RNA interaction probing assays. RNA probing assays of the complex HH363 -10/IRES were performed with 32 P 5' end-labeled inhibitor RNA. Complexes were constructed as described in [17] by incubating 50 fmol 32 P 5'-end-labeled HH363 -10 (~500 CPM) with 20 pmol non-labeled HCV RNA. Control reactions were performed in the presence of a non-related RNA (RNA 667). Digestion reactions were initiated by the addition of RNase T1 (0.1 U), RNase A (0.2 ng) or lead acetate (15 mM), and incubated at 48C for 2 min, 30 min and 20 min, respectively. An equal volume of denaturing loading buffer supplemented with EDTA 100 mM was added, and the products resolved on high resolution denaturing polyacrylamide gels (8 -20 %). These were dried and scanned as above. For RNase H-mediated degradation, 50 fmol 
). Complexes were basically formed as described [17] . A final RNase H (USB) concentration of 5 U/ml was used to initiate the degradation. Digestion reactions were incubated for 10 min at 378C and stopped on ice. Specific products were resolved on 6 % high resolution denaturing polyacrylamide gels, dried, and scanned as described above.
Ribosome-IRES complex assembly assays. The identification of 48S and 80S particles was essentially performed as described by Ray et al. [24] . Briefly, a concentration of 40 nM of 32 P-internally labeled RNA IRES-FLuc (~200 000 dpm) was incubated with 5 mM inhibitor RNAs and 5 ml translation reaction mix containing 4 ml RRL. To prevent the formation of the 80S particle, the translation mix was supplemented with 2 mM 5'-guanylyl imidophosphate (GMP-PNP, Sigma Aldrich). The reactions were incubated at 308C for 60 min and stopped on ice. The mixtures were then diluted to 150 ml with gradient buffer (20 mM TrisHCl pH 7.5, 100 mM KCl, 3 mM MgCl 2 , 1 mM DTT) and loaded onto a continuous 10 -30 % linear sucrose gradient. Ribosomal complexes were resolved by ultracentrifugation at 30 000 rpm for 4 h in a SW40 Ti rotor. Fractions of 500 ml were collected from the top of the gradient and their radioactivity was measured using a QuickCount QC-4000/XER Benchtop Radioisotope Counter (Bioscan, Inc.).
Transfection of RNA molecules into Huh-7 cells.
Human hepatoma cells (Huh-7) were grown in Dulbeccos modified Eagle medium (DMEM) supplemented with 10 % heat-inactivated fetal bovine serum (FBS; Invitrogen) and 2 mM L-glutamine (Sigma), at 378C in a 5% CO 2 atmosphere. At 30 h before transfection, 120 000 cells were seeded onto a 24-well plate. A mix containing 1 mg mRNA IRESFLuc, 0.5 mg RLuc, 50 ml Opti-MEM (Invitrogen) and 1.5 ml transfection reagent (TransFectin TM , BioRad) was complemented with 50 ml Opti-MEM , with or without inhibitor RNA. The amounts of inhibitor employed in these assays were established at 0.7, 1.4, 2.7, 4 and 5.4 mg. The total amount of RNA was the same for all transfections (7 mg); this was achieved by complementing with a non-related 80-nt long RNA molecule (RNA 80 ). RNA molecules were denatured, and then renatured, before transfection as above. The lipid-RNA complex was added to the Huh-7 cells and incubated for 18 h at 378C [25] . Firefly and Renilla luciferase activities were determined using the DualLuciferase TM reporter assay system (Promega).
Results
In vitro inhibition of IRES-dependent translation by a collection of chimeric RNAs. We previously described the isolation by in vitro selection of a collection of 30 RNA molecules that specifically target the HCV IRES [17] . All the selected variants were classified into seven families defined by common sequence motifs. One representative of each group was analyzed for its ability to interfere with IRES function in coupled transcription-translation systems. A significant inhibitory activity was detected for the seven tested molecules [17] .
To further survey the potential IRES-inhibition function of each selected variant and to exclude any nonspecific effect over transcription, in vitro translation assays of monocistronic IRES-FLuc and capRLuc mRNAs have been performed using RRL in the presence of the different inhibitor RNAs. IRES activity was measured as the synthesis of FLuc protein and compared to the levels of RLuc, which is translated in a cap-dependent manner. All the molecules inhibited IRES function at a concentration of 5 mM, some of them by as much as 90 % (Fig. 2) . The difference in the experimental approach (translation instead of transcription-translation) might explain the apparent discrepancies in the observed inhibition data presented here and those previously published [17] . No significant effect was seen on cap-dependent translation (< 5 %, data not shown) for any of the assayed molecules at the concentration tested, indicating a selective inhibition of IRES function. Since all the RNA molecules shared the HH363 domain, presumably both the targeting site of the aptamer and the structure of the whole inhibitory molecule are associated with the potency of each inhibitor.
HH363 -10 potently interferes with IRES-dependent translation in vitro. We focused on HH363 -10, which strongly blocked IRES-dependent translation by up to 90 % (Fig. 2) . The aptamer sequence contains a motif complementary to the highly conserved domain IIIf of the HCV 5'UTR ( Fig. 1 ; [17] ), suggesting it to be a possible interaction site. This observation led us to study in detail its activity in in vitro translation assays. Several concentrations of HH363 -10 were tested, ranging from a molar ratio IRES-FLuc:HH363 -10 of 4:1 to 1:125. Strong, dose-dependent inhibition of IRES-dependent translation was observed, with an IC 50 value of 150 nM ( Fig. 3 and Table 1 ). Further, at the lowest concentration of the inhibitor tested, a significant reduction in the FLuc levels was achieved (around 20 %). This effect was specific for IRESdependent translation, since the synthesis of RLuc protein was not affected even at the highest concentrations assayed (< 5 %, data not shown). To corroborate the specificity of HH363 -10 for the HCV IRES, a control experiment was performed in which the synthesis of FLuc protein was mediated by the EMCV IRES and normalized with respect to RLuc levels. No significant changes in IRES activity were detected in the presence of HH363 -10 ( Fig. 3) , validating its potential as a specific HCV IRES inhibitor. The contribution of the two activities (cleavage by HH363 and binding by Ap10) to the inhibitory capacity of the chimeric molecule was further analyzed. Although they both clearly reduced FLuc levels on their own in a dose-dependent manner, their action was significantly less than that exerted by the entire HH363 -10 molecule at every assayed concentration ( Fig. 3 and Table 1 ). A fall in inhibitory activity was also observed (as well as a 12-fold increase in the IC 50 value) when both HH363 and Ap10 were simultaneously added to the translation reaction. This indicates that the combination of the two inhibitory domains in a single molecule is required to reach the strongest inhibition.
Cleavage of RNA IRES by HH363 -10. The capacity of HH363 -10 for processing IRES RNA was previously analyzed in vitro in the absence of any protein factor. A molecule containing the first 691 nt of the HCV-1b genome (5'HCV-691; [17] ), comprising the whole IRES to allow ribosome assembly and translation [4] , was specifically cleaved at the expected site (Romero-López et al., unpublished data). We wanted to explore the HH363 -10 capacity to process the HCV IRES in the presence of translation factors. For this purpose, 40 nM internally radiolabeled 5'HCV-691 RNA was incubated with different amounts of HH363 -10 in RRL (see Materials and methods). The proportion of the specific cleavage products increased with increasing amounts of the catalytic RNA, showing a concentration-dependent effect (Fig. 4) . Cleavage activity was compared with that of HH363. It showed a slight reduction in the amount of the reaction products in comparison to the chimeric inhibitor (Fig. 4) . The improvement in the processing efficiency of HH363 -10 in RRL with respect to HH363 may partially reflect the enhancement of the inhibition detected for the chimeric inhibitor.
Identification of the interacting sites between HH363 -10 and the IRES region. We previously identified a sequence within the aptamer, A 46 UUC-GUAA 53 , complementary to the IRES IIIf domain ( Fig. 1; [17] ), suggesting its involvement in the interaction with the IRES. Secondary structure analysis and experimental mapping of the residues involved in the interaction was undertaken to validate this hypothesis. We initially determined the interacting sequence in the IRES region. For this, a 5'-end radiolabeled RNA Values are the mean of at least three independent trials. Research Article containing the full 5'UTR was used as a substrate (5'HCV-356; [17] ). RNase H probing assays were performed using a 9-mer DNA oligonucleotide, asIRES305, complementary to the loop of domain IIIf (see Materials and methods). A specific RNase H cleavage product with the expected length was identified (305 nt; Fig. 5a ). Increasing amounts of HH363 -10 promoted a significant and dose-dependent reduction in the amount of the degradation product (Fig. 5a, c) . This indicates that domain IIIf is involved in the binding between the chimeric inhibitor and the IRES. No effect on the RNase H cleavage pattern was observed when a DNA oligonucleotide complementary to positions 196-204 of the HCV genome was used in the presence of HH363 -10 (asIRES196; Fig. 5b, c) , demonstrating the specificity of the interaction. RNase and lead probing assays were subsequently performed to analyze the secondary structure of HH363 -10 and to identify the residues involved in the association to domain IIIf. The inhibitor RNA was 5' end-labeled with 32 P and incubated with a molar excess of a non-related RNA (RNA 667). Partial digestion with nucleases (RNase T1 and RNase A) and lead was subsequently performed. Cleavage mainly occurred at specific single-stranded positions (G nucleotides for RNase T1 probing, C or U residues for RNase A reactions and any nucleotide for lead treatments). The degradation pattern of HH363 -10 was used for secondary structure predictions using Mfold software [26] . This showed the exposure of nucleotides A 46 UUCGUAA 53 in an apical loop (Fig. 1b, Fig. 6 ). Further in silico structural analyses with the PknotsRG program predicted the formation of an intramolecular pseudoknot involving the nucleotides A 46 -G 50 and C 63 -U 67 (Fig. 1b, Fig. 6 ). The results were compared with those in the presence of the IRES to map the residues involved in the Research Article cleavage (Fig. 6 ), suggesting their involvement in the interaction of HH363 -10 with the IRES. Further, residues C 63 -U 67 showed greater sensitivity to the hydrolytic reagents in the presence of the substrate 5'HCV-691gg. This was in good agreement with the formation of an intramolecular pseudoknot structure in the inhibitor. These results confirm the initial hypothesis that the IIIf domain is the interaction site for HH363 -10. To our knowledge, this is the first report describing an RNA aptamer targeting the HCV IRES pseudoknot motif.
HH363 -10 prevents the assembly of the 80S ribosomal complex. Domain IIIf of HCV IRES has been suggested a crucial motif for the recruitment of the 40S ribosomal subunit in the formation of the 48S particle. It is also reported to be involved in the subsequent structural RNA IRES rearrangements that finally lead to the formation of an active 80S translational complex [19, 29, 30] . The effect of HH363 -10 on HCV IRES-mediated ribosome assembly was therefore examined. For this, in vitro translation reactions containing 32 P-labeled mRNA IRES-FLuc were performed in the presence or absence of a 125-fold molar excess of HH363 -10. The 48S and 80S particles were analyzed by sucrose density gradient ultracentrifugation (see Materials and methods). After fractioning, they were detected as two different and well-defined peaks when no inhibitor was added (Fig. 7) . Experimental conditions were established to reproducibly achieve efficient formation of the 48S and 80S complexes in the absence of inhibitor. The addition of HH363 -10 reduced the formation of the 80S complex, whereas the 48S particle was clearly produced (Fig. 7) . These data were confirmed in subsequent independent assays (data not shown). A similar result was obtained when reactions were incubated with GMP-PNP, a non-hydrolysable GTP analog that blocks the progression of a translation initiation complex at the 48S particle stage (Fig. 7) . Similarly, an evident reduction in 80S complex accumulation was detected in the presence of Ap10 (Fig. 7) , while no significant changes were observed when HH363 was present (Fig. 7) . These observations suggest that the prevention of 80S particle formation is related to the inhibition exerted by HH363 -10 and Ap10; this inhibition is explained by their binding to the IIIf domain.
Inhibition of IRES function by HH363 -10 in a human liver cell line. The effect of HH363 -10 on IRES function in cell culture was also examined. A mixture of the IRES-FLuc and cap-RLuc transcripts was cotransfected with HH363 -10 into a hepatocellular carcinoma cell line (Huh-7) that supports efficient HCV replication. A dose-dependent study was performed to determine the activity of the inhibitor. HH363 -10 appeared as an effective and specific inhibitor of IRES-dependent translation, reducing FLuc activity by up to 50 % at 300 nM (Fig. 8) without affecting to that shown by RLuc (<5 %; data not shown). Since the strongest inhibitory effect resides in the complete molecule, a collection of mutants was constructed to further study the contribution of the cleavage and binding activities to the inhibitory function of HH363 -10 (Fig. 1b) . This included a catalytically non-active derivative (HH363 m-10), a null variant for the interaction site in the aptamer (HH363 -10 m), and a completely inactive molecule containing both modifications (HH363 m-10 m; Fig. 1b) . These mutations involve a small number of changes in the nucleotide sequence, but they entail a complete loss of function. Modifications in the 
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C. Romero-López, R. Díaz-Gonzµlez and A. Berzal-Herranz A small RNA interferes with HCV IRES function catalytic core led to a full loss of cleavage activity and mutations in the aptamer domain completely abolished association with the IRES (data not shown). Inhibition assays showed that functionality in cells was also severely affected by these mutations. Single mutants mildly inhibited IRES-dependent translation, whereas no inhibitory effect was observed for the HH363 m-10 m construct. This result suggests that the strongest inhibitory activity is an intrinsic feature of the entire HH363 -10 molecule combining both activities.
Discussion
The search of novel therapeutic strategies to fight against HCV infection is a major goal. The high variation rate of the viral genome leads to the appearance of populations comprising a spectrum of genomic sequences, in which variants resistant to treatment emerge and contribute to the progression of the disease [1] . In recent years, this has been outlined as the main difficulty in achieving effective therapies and has imposed the necessity of searching new targets. Classical medical approaches targeting essential HCV proteins were considered excellent strategies for a long time. However, mutations conferring resistance to the treatment have been reported [31] . Efforts were subsequently focused on interfering with highly conserved genomic regions. The great advances in the antisense and siRNA technology prompted the idea of an efficacious therapy in the near future, but in many cases the emergence of resistant viral genomes has been observed for HCV and other viral infections [9] [10] [11] [12] [13] . One of the most promising approaches is the specific recognition of highly structured regions in the genomic RNA that importantly retain a conserved sequence and structure and fulfill essential roles in viral translation and replication. They interact with viral and host proteins to carry out these essential functions for the viral maintenance and propagation. This means that the preservation of both primary and secondary structure in those RNA domains is crucial for the conservation of the function [18] . It has been shown that mutations that preserve the secondary structure of the IRES pseudoknot also result in a drastic reduction of the in vitro translation efficiency [18] . This is in good agreement with the high sequence conservation observed in this domain among different HCV isolates [32] . In this context, targeting the HCV IRES region is an excellent therapeutic option. The use of ribozymes and aptamers as anti-HCVagents has been extensively reported [8] . Aptamers are considered an excellent option to target highly folded RNA domains [33] [34] [35] . In contrast to antisense, for which interaction with complex structured domains is severely restricted, aptamers only require a short stretch of complementary nucleotides in an appropriate structural context to exhibit high affinity and efficiency. Further, the development of combination therapies using antiviral compounds with different specificities would additionally contribute to preventing the emergence of resistant viral pools [1, 14, 15] . The functional characterization of HH363 -10, which simultaneously targets two highly conserved regions that are required for the preservation of the IRES activity [18, 36, 37] , clearly shows the advantage of combining two inhibitory activities in a single molecule to achieve a strong effect, making our strategy an excellent starting point for the development of new therapeutic tools. The chimeric RNA HH363 -10 strongly inhibited HCV IRES-dependent translation in vitro, with an IC 50 of 150 nM. This value is considerably lower than those reported for a decoy RNA of the stem-loop IIIef and for two aptamers of the IRES targeting domains II and IIId [24, 33, 35] , but is slightly higher than that obtained for an antisense RNA of the IIId domain [25] . Since HH363 -10 combines two inhibitory activities targeting different domains of the HCV genome, it might result in a more effective anti-HCV agent, although this requires further analysis. HH363 -10 also showed inhibitory activity of the HCV IRES function in a hepatoma cell line, although to a less extent than that seen in vitro. This discrepancy has been reported previously [24] . Ray and Das [24] described differences in the inhibition of HCV IRES exerted by small RNAs between in vitro and in cell culture experiments. Further, they reported different inhibition levels in two cell lines, HeLa and Huh-7, under similar experimental conditions. It has also been shown that HCV-IRES activity is dependent on the concentration of different translation trans-acting factors. Salt concentrations and the cell cycle phase may influence the HCV-IRES efficiency [38 -40] . Differences in inhibition levels can also be the result of the different concentrations of RNA at the right cellular compartment compared to the in vitro experiments.
It is noteworthy that the activity of the entire molecule is significantly greater than that measured for the components as independent molecules, HH363 and Ap10. This is consistent with the fact that Ap10 was isolated by the in vitro selection process attached to HH363. This, together with the fact that mutations that block either the catalytic activity of the hammerhead ribozyme or the association via the aptamer domain negatively affect the inhibitory capacity of HH363 -10, highlights the need for the selected fulllength molecule conserving both inhibitory activities if maximum inhibition is to be attained. Although only a low proportion of specific cleavage products are generated by the HH363 -10 in RRL, the abolishment of the catalytic activity negatively influences the inhibitory properties of HH363 -10, meaning that it contributes to the global inhibitory effect, although to a low extent. Besides the cleavage activity, we cannot discard a possible antisense effect of the catalytic domain. It is also likely that a structural stabilization of the aptamer domain is mediated by the HH363 motif. An improvement in the access to the domain IIIf is feasible too. We suggest that the binding of HH363 -10 to its target is the key step in its mechanism of action, and that the recognition of the primary, secondary and tertiary structure in the substrate is the essential point to achieve the effectiveness of the inhibitor. None of these possibilities can be ruled out, nor are they mutually exclusive. Other explanations may also be possible. We suggest that the observed inhibition is an intrinsic property of HH363 -10, and we cannot define the exact contribution of each activity. It should be also noted that the combination of both inhibitory activities may contribute to reducing the chance of appearance of resistant viral pools. The results show that domain IIIf of the HCV IRES is involved in the interaction with HH363 -10 ( Fig. 5 ).
To our knowledge, this is the first report describing an RNA aptamer that specifically interacts with the pseudoknot structure of the HCV IRES. We do not, however, have any information about the nature of this interaction. Nucleotides involved in the association between the inhibitor and the substrate map in apical loops (Figs 5 and 6 ). It would be therefore plausible that tertiary restricted kissing interactions are established. Since domain IIIf participates in the formation of a pseudoknot structure, it seems likely that an additional contribution is required to destabilize this motif and promote the kissing between HH363 -10 and the IRES. We hypothesize that residues G 41 A 42 G 43 , complementary to positions 325 to 327 at the 3'end of the pseudoknot structure in the IRES, are working in that way. This is supported by the fact that they show a decrease in their sensitivity to RNase-mediated cleavage in the presence of the substrate RNA (Fig. 6) . From a structural and functional point of view, these results are of clear interest. Domain IIIf shows strong sequence and structure conservation among different isolates and has an important role in IRES function [18] [19] [20] . Distortions in its architecture dramatically affect viral polyprotein translation [18] . The present data show that, as a result of the association of HH363 -10 to IRES through the IIIf domain, the formation of the 80S particle in vitro is almost completely abolished (Fig. 7) , which may explain the inhibitory activity of HH363 -10. All these features make it an excellent target for HCV inactivation assays. In summary, the combination of antiviral agents with different specificity and activity in a sole molecule is a novel strategy that could provide a good way of restraining the emergence of resistant variants, and may be extended to other viral infections, such as HIV. The anti-IRES properties shown by HH363 -10 both in vitro and in cell culture call for its mechanism of action and activity in viral culture systems to be thoroughly investigated. Work in this area is currently underway at our laboratory. Finally, this chimeric molecule has potential as a biochemical tool for studying RNA-RNA interactions and investigating the role of the pseudoknot structure in the HCV cycle.
